Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs
NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive...
Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection
Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: ...
Expanded coverage, supported by published data from the Vall d’Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor...
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and...
Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 M edicare coverage secured for lung cancer surveillance, providing a...
Barchart Research What to Expect from PSNL Earnings PSNL Generated May 6, 2026 Current Price $6.07 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 13.12% Personalis Prepares to Explain...